Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase
about
Current perspectives on HIV-1 antiretroviral drug resistanceStructures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA.Intracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and quantitation in extracts from quiescent- and activated-lymphocyte subpopulations.Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excisionThe Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidineHuman immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.The "Connection" Between HIV Drug Resistance and RNase HThe N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.HIV-1 antiretroviral drug therapy.Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovirA novel mechanism of selectivity against AZT by the human mitochondrial DNA polymerase.Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain: effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked DNMolecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs.The Y181C substitution in 3'-azido-3'-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.Trapping HIV-1 reverse transcriptase before and after translocation on DNA.Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants.Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure.Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation.Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC.Effects of primer-template sequence on ATP-dependent removal of chain-terminating nucleotide analogues by HIV-1 reverse transcriptase.The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.
P2860
Q26852626-1B356B50-3925-4A3D-AD5B-B7D34B168FB3Q27640046-7CAB81D2-C979-42F2-8A3B-68F5F1A33694Q33770095-A00EE128-5A23-4A78-9663-266B2C952FB5Q33836938-76845A27-DC24-409F-AF13-A8B46A52E910Q33889635-B040EA6F-E7C6-4DB6-930A-156C3473DADFQ33896402-E04C7D1B-7AD6-45C2-8C9C-81EE232CB10FQ33935229-C4451365-AA9D-40C0-A817-E60C81545791Q33987492-C26151BC-9600-43FD-9B9E-8BE5EB53134CQ34313605-DECC7561-3BD8-4549-A644-875BE703F941Q34352431-DDB0F337-EACD-4972-B422-42E55BF6DEDFQ34996622-205652A9-C1A1-4CAC-BD69-5BF3DC98E967Q35853012-8A6C1369-1202-493E-95FB-C179F86B877BQ35912746-AB382D36-78EC-448E-8914-963E1C68642CQ36328820-F4693BC9-C370-4201-A9D7-12F149D2D710Q36553113-92D740E3-F97C-4A2E-87B5-C65D2C8E4081Q36928993-9A809671-7507-47E9-88A8-F8ECAAA0214FQ36964321-33E48348-88B2-470B-82FF-95DD31202B8CQ37492877-815FAD8E-F923-4AEA-A6E5-5CE096CBA1A4Q38343144-05E84104-65B9-4C1A-967A-48CCC5558276Q38344427-F4D6F230-57E7-4B40-8266-937153F42A8DQ38346006-536EE374-5505-40D4-B9EA-103B16583425Q38351813-B4B022B6-8E07-48B8-BEF0-5EAF0EF44523Q38358259-D6DE1E1E-8BAD-4503-A4BC-2796ACB9EF33Q39077432-673B4B22-7C73-4E57-B46D-2563C3004C03Q39664167-6AB50232-1342-4AA4-B07F-B4A45C5C3738Q39732544-A1F3D02A-2AC2-4708-A267-028D7EC04876Q40173457-8B14D84D-F855-4300-964C-52AD4E017A15Q41262484-EFF85C97-BA93-4295-84E7-1167C49BD4BDQ41862836-FE6B0002-C726-4572-A3C8-66EF390B2898Q42117884-4AD8C654-96D7-43AA-972A-4F4368FC550EQ44486147-5701282D-6563-47F9-868B-EA3CFAC4D752Q45016660-91270F38-B360-4461-A728-5D2A7D7FE95FQ46718140-D80F09C3-C423-4859-B72A-A09A9F7FE054Q47560712-AC8051DC-BE7A-4263-8F2F-9AA6D95C4D6E
P2860
Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Effects of specific zidovudine ...... s type 1 reverse transcriptase
@en
Effects of specific zidovudine ...... type 1 reverse transcriptase.
@nl
type
label
Effects of specific zidovudine ...... s type 1 reverse transcriptase
@en
Effects of specific zidovudine ...... type 1 reverse transcriptase.
@nl
prefLabel
Effects of specific zidovudine ...... s type 1 reverse transcriptase
@en
Effects of specific zidovudine ...... type 1 reverse transcriptase.
@nl
P2093
P2860
P1476
Effects of specific zidovudine ...... s type 1 reverse transcriptase
@en
P2093
Antero G So
Ingrid Pfeifer
John W Mellors
Peter R Meyer
Suzanne E Matsuura
Walter A Scott
P2860
P304
P356
10.1128/AAC.46.5.1540-1545.2002
P407
P577
2002-05-01T00:00:00Z